BofA Securities has recently initiated Surgery Partners Inc (SGRY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on October 14, 2024, UBS had initiated the stock to Buy, setting a price target of $38. KeyBanc Capital Markets also initiated Sector Weight rating. Additionally, Macquarie initiated Outperform rating on June 28, 2024, with a target price of $31. Barclays analysts, in their report published on March 6, 2024, also initiated Equal Weight rating and set a price target of $35 for Surgery Partners Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Surgery Partners Inc (SGRY) Stock Trading Recap
On Wednesday, Surgery Partners Inc (SGRY) stock saw a modest uptick, ending the day at $25.79 which represents a slight increase of $0.09 or 0.35% from the prior close of $25.7. The stock opened at $25.71 and touched a low of $25.5 during the day, reaching a high of $26.15. The volume of shares traded was 1.08 million falling short of the average volume of 1.46 million.
Sponsored
SGRY Stock Performance and Moving Averages
In recent trading, Surgery Partners Inc (SGRY) stock price has shown some volatility, fluctuating 0.16% over the last five trades and 22.34% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -10.20%, and it has plunged by -10.30% in the previous three months. Currently, SGRY is trading at 15.53%, 17.56%, and -3.13% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, SGRY, a Healthcare sector stock, is trading -26.93% below its 52-week high but remains 32.26% above its 52-week low. The Average True Range (ATR) (14 days) of 0.97 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Surgery Partners Inc’s Profitability and Valuation Ratios
Surgery Partners Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 14.48% and a profit margin of -2.03%, with a gross margin of -10.20%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Surgery Partners Inc’s market capitalization stands at $3.28 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 26.85. Additionally, the Price-to-Sales Ratio is 1.1, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.73, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 41.82% of Surgery Partners Inc (SGRY)’s shares, while financial institutions hold 73.61%.
Notable insider trades include Bane Harrison R., National Group President at Surgery Partners Inc (SGRY), who sold 6325 shares on Sep 04 ’24, at $31.11 each, totaling $0.20 million. On Jun 12 ’24, Burkhalter Danielle, Chief Human Resources Officer, sold 6000 shares for $26.39 each, amounting to $0.16 million. Additionally, on May 31 ’24, Owens Bradley R. sold 6000 shares at $27.65 each, generating $0.17 million.
